Re: Leclercq et al.: Anti-tumor necrosis factor-α versus tocilizumab in the treatment of refractory uveitic macular edema: a multicenter study from the French Uveitis Network (Ophthalmology. 2022;129:520-529)

Ophthalmology. 2022 Jul;129(7):e77. doi: 10.1016/j.ophtha.2022.02.019. Epub 2022 Mar 25.
No abstract available

Publication types

  • Letter
  • Multicenter Study
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Humans
  • Macular Edema* / diagnosis
  • Macular Edema* / drug therapy
  • Macular Edema* / etiology
  • Tomography, Optical Coherence
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha
  • Uveitis* / diagnosis
  • Uveitis* / drug therapy

Substances

  • Antibodies, Monoclonal, Humanized
  • Tumor Necrosis Factor-alpha
  • tocilizumab